

RESOLUTION OF OXIRANES. APPLICATION TO THE SYNTHESIS
OF THE PLATELET AGGREGATION FACTOR

Bernard CIMETIERE, Laurent JACOB et Marc JULIA*

Ecole Normale Supérieure, Laboratoire de Chimie, Associé au CNRS
24 rue Lhomond, 75231 Paris Cédex 05

Abstract - Resolution of racemic oxiranes has been achieved through their conversion into hydroxy sulfonium salts of dibenzoyltartaric acid. Thus, resolution of *n*-octadecyl glycidyl ether followed by reaction with phosphorylcholine and acetylation led to C₁₈-P.A.F.

Whereas optically active β-hydroxy oxiranes are now readily available through the Sharpless reaction¹, simple oxiranes are not so easily prepared in optically active form².

The reaction of oxiranes with thioethers and acids, which surprisingly was not known³, occurred easily to give high yields of the β-hydroxy sulfonium salts resulting from terminal attack on the 1,2-oxiranes. The onium ion provides a handle for resolution with optically active acids. In the event, (L)-dibenzoyltartaric acid (DBTA) proved efficient to bring about the resolution. The less soluble diastereoisomer was then converted by base into the optically active oxirane (Table 1).

Opening an oxirane with a secondary amine followed by resolution of the amino alcohol thus produced, followed by quaternization and treatment with base has been proposed⁴ to achieve resolution. In the case of oxirane 1c, this technique has been compared with the sulfonium ion approach and found much less efficient.

The optically active acid can be used directly for the opening of the oxirane ring but little kinetic resolution was observed with DBTA. Recently, kinetic resolution has been observed in the reaction of oxiranes with thiols catalysed by zinc tartrate⁵.





1a R = Et1b R = n-Hex1c R = nC₁₈H₃₇-OCH₂1d trans 2,3-epoxybutane

Table 1 : RESOLUTION OF OXIRANES

oxirane	acid	Step 1 ^a		Step 2		Step 3	
		time h	Yield <u>2</u> %	number of recrystallisations (solvent)	Yield <u>2</u> [*] %	Yield <u>1</u> [*] %	ee <u>1</u> [*] (major enantiomer)
<u>1a</u>	(L)-DBTA	24	99	7 (EtOH)	16	35 ^b	92.5 ^c (S)
<u>1b</u>	HF ₄ aq. 34%	0.5	95	6 (acetone) ^d	6	88 ^b	98.5 ^c (S)
<u>1c</u>	(D)-DBTA	24	76-90	8 (MeOH)	25	100	95 ^f (R)
<u>1d</u>	(L)-DBTA	0.5	60	4 (EtOH + acetone 3 : 1)	16	85 ^b	91.5 ^c (S, S)

^a 1 eq. oxirane 1M in CH₂Cl₂, 1 eq. acid, 5 eq. dimethyl sulfide, 20°C.^b Determined by GLC with an internal standard.^c The ee have been kindly determined by Prof. V. Schurig and Dr. U. Leyrer by GLC on a chiral column.^d After exchange of BF₄⁻ for DBT⁻.^e Recrystallisation of the (D)-dibenzoyltartrate salt.^f Determined by ¹H NMR with Eu(hfc)₃ after opening the oxirane ring by sodium methoxide⁶



- a**⁹ NaOH 50%, Aliquat 336, cyclohexane, reflux;
99% yield, m.p. 40-41°C (litt.¹⁰ m.p. 38-39°C)
- b,c,d** See table 1; $\underline{1c}^*$: m.p. 40-41°C (litt.¹¹ m.p. 41-42°C)
- e**¹³ Phosphorylcholine, AcOK cat., MeOH, reflux
- f** Ac₂O, DMAP, CH₂Cl₂;
36% yield from $\underline{1c}^*$ (after flash chromatography on silica gel 230-400 mesh)
- g** Litt. m.p. 260°C¹¹, 210°C (dec)¹⁴, 212-215°C (dec)¹⁶
- h** $[\alpha]_D^{24} = -1.9^{\circ}$ ($c = 0.5, CHCl_3$) for an authentic sample from BACHEM.

An obvious application was the production of glycidol derivatives¹ which are useful intermediates for the synthesis of drugs or phospholipids⁷. We selected as our target the Platelet Aggregating Factor 4, several syntheses of which have been published⁸.

The optically active oxirane $\underline{1c}^*$ (ee = 95 ± 3%) was treated with phosphorylcholine and potassium acetate in methanol. After evaporation, washing with ether and drying, the crude lyso-PAF 3 was acetylated to give PAF 4 which was identical with an authentic sample as shown by ¹H NMR¹⁴ and biological activity¹⁵.

This route is being applied to the synthesis of other phospholipids.

Financial help from the CNRS (UA 1110) is gratefully acknowledged.

REFERENCES

- 1 R.M. Hanson and K.B. Sharpless, *J. Org. Chem.*, 1986, 51, 1922-1925 and references cited therein.
- 2 A literature survey will be given in the full paper.
- 3 P.A. Lowe, in *The chemistry of sulfonium group*, C.J.M. Stirling Ed., Wiley, New-York, 1981, p. 271.
- 4 R.K. Hill, *J. Amer. Chem. Soc.* 1958, 80, 1611-1613.
- 5 H. Yamashita, T. Mukaiyama, *Chem. Letters* 1985, 1643-1646.
- 6 M.J. de Smet, B. Witholt, H. Wynberg, *J. Org. Chem.* 1981, 46, 3128-3131.
- 7 C.M. Lok, A.P.J. Mank, J.P. Ward, *Chem. Phys. Lipids* 1985, 36, 329-334.
- 8 M.C. Venuti, *Annu. Rep. Med. Chem.* 1985, 20, 193-202.
- 9 Kao Soap Co., Ltd, *Jpn. Kokai Tokkyo Koho* 81 63,974 , *Chem. Abs.* 1981, 95, P 187047x.
- 10 R. Pozniak, J. Chlebicki, *Pol. J. Chem.* 1978, 52, 1283-1288.
- 11 G. Hirth and R. Barner, *Helv. Chim. Acta*, 1982, 65, 1059-1084.
- 12 A.E. Gal, F.J. Fash, *Lipids*, 1977, 12, 314-315.
- 13 K. Sasse in *Houben-Weyl, Methoden der Organischen Chemie*, Vol.XII/2 G. Thieme Verlag, Ed. E. Müller, Stuttgart, 1964, p.p. 160 and 238.
- 14 F. Heymans, E. Michel, M.-C. Borrel, B. Wichrowski, J.-J. Godfroid, O. Convert, E. Coeffier, M. Tence, J. Benveniste, *Biochim. Biophys. Acta* 1981, 666, 230-237 ; we thank Dr. Godfroid for the authentic spectrum.
- 15 The biological activity was kindly determined by Dr. Sedivy (Rhône-Poulenc Laboratories) according to J.F. Mustard, D.W. Perry, N.G. Ardlie, M.A. Packham, *Brit. J. Haematol.* 1972, 22, 193-204 and G.V.R. Born and M.J. Cross *J. Physiol.* 1963, 168, 178-195.
- 16 M. Ohno, K. Fujita, H. Nakai, S. Kobayashi, K. Inoue, S. Nojima, *Chem. Pharm. Bull.* 1985, 33, 572-582.

(Received in France 9 October 1986)